Amsterdam, The Netherlands – 04 June 2019
Jouvene’s new innovative offer will empower people with disease prevention, detection, diagnosis, treatment and management.
With more than 10,000 diseases and medical conditions linked to DNA mutations, Whole Genome Sequencing is the Gold Standard for Genetic Diagnostic and the way of personalized medicine. By analysing their genetic map, people obtain essential information so that they can make the best decisions regarding disease prevention and management practices.
Whole Genome Sequencing (WGS) is the state-of-the-art technology to decrypt and comprehend an individual in a Single Essay. The complete DNA make-up of an individual is revealed in order to identify the diseases that are most likely to affect him and what are the possible ways to prevent these diseases.
Also, Stem cells are essential cells in the way they contribute to the development of all tissues, organs, and systems in the body. They are able to transform into other types of cells in the body to create new growth and development.
Umbilical cord blood is an abundant source of stem cells that are genetically related to the baby and his family. They are too valuable and worth saving in case of future need for treatment of a disease.
Jouvene is part of the group with a proven track record of cord blood unit release and successful therapy of life-threatening conditions. With more than 330,000 samples stored and several processing and storage facilities, the long-established professionalism, expertise of the team and state of the art technology is recognized by medical community providing the basis for a strong and reliable organization.
Jouvene represents the focus point of the two technologies mastered by the sisters companies of the group, CryoSave and Genoma Swiss Biotechnology and therefore advocates for Personalized Medicine providing the right treatment to the right individual at the right time.
Jouvene’s exclusive genomics technology, fully certified has been validated over several thousands of samples enabling people to have a better knowledge about their own health.
CEO of Esperite, Frederic Amar says: “Our purpose is to provide people with most relevant actionable genetic information to take appropriate medical decisions with their doctors. Today progress in the research and clinical care enabling personalized medicine has great potential to a new and better approach to health based on each person's unique genetic makeup”.
Jouvene baseline speaks by itself: You owe it yourself, you owe it to your family.
Visit www.jouvene.com,and get assured of a healthy life for you and your family.
About ESPERITE
ESPERITE group, listed at Euronext Amsterdam and Paris, is a leading international company in regenerative and precision medicine founded in 2000.
To learn more about the ESPERITE Group, or to book an interview with CEO Frédéric Amar: +31 575 548 998 - ir@esperite.com.
Attachment
